RESPIRATORY SYNCYTIAL VIRUS TREATMENT UPDATES

Date: 11/28/23

The Centers for Disease Control and Prevention (CDC) issued an official health alert on October 23 about the availability of Beyfortus® vaccine for Respiratory Syncytial Virus (RSV) due to limited manufacturer supplies. Because the common respiratory virus that causes mild cold like symptoms can cause more serious illnesses like bronchiolitis and pneumonia in vulnerable populations the CDC published its recommended vaccine prioritization.

Palivizumab (Synagis®) is covered under Meridian’s drug plan and requires prior authorization (PA), per the September 29, 2023 HFS notice. Meridian PA criteria are based on national published guidelines and recommendations; see our October 2023 updated guidelines (PDF).

Please consult Meridian’s previously published new RSV medications guidelines for Abrysvo® and Arexvy® based on FDA indications.